Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Potent new p38 MAP kinase inhibitor suppresses cytokine release, skin inflammation

Sep. 27, 2001

Final phase I/II clinical data presented at European psoriasis meeting for siplizumab

Sep. 25, 2001

Broad development program under way for siplizumab

Sep. 19, 2001

Castor oil component demonstrates both pro- and antiinflammatory properties

Sep. 18, 2001

Allergan's Botox cleared in Canada for treatment of axillary hyperhidrosis

Sep. 13, 2001

Antiscarring PCP inhibitors in the Pfizer pipeline

Sep. 12, 2001

Cellegy seeks MCA approval of Rectogesic for treatment of anal fissures

Sep. 10, 2001

Ortec's OrCel approved for healing donor site wounds in burn victims

Sep. 10, 2001

PH-10 enters phase I study for treatment of actininc keratosis

Aug. 30, 2001

Enbrel shows positive results in phase II clinical study of psoriasis

Aug. 28, 2001

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...